Allakos Therapeutics (ALLK): Price Target Chart
This price trend chart for Allakos Inc. (ALLK) illustrates the dynamics of an asset whose profits are based on the creation of advanced antibodies against allergies and inflammation, with the current indicator standing at 0.40. Allakos Inc. (ALLK) focuses on therapies for dermatological and gastroenterological pathologies, targeting the massive chronic disease market. Due to its independence from the global economy and stable demand for pharmaceuticals, the business serves as a reliable defensive asset.
Analytical breakdowns for Allakos Inc. (ALLK)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Allakos Inc.|ALLK - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital allakos.com|ALLK - Company Aggregate Debts|Debts to Book Capitalization Allakos Therapeutics|ALLK - Company Long-Term Debt|Company Short-Term Loans and Borrowings Allakos|Quick Liquidity Indicator allakos.com
- financial results and valuation multiples details:
ALLK - Net Profit|Projected Future Earnings Allakos Inc.|ALLK - Price to Earnings Ratio|Future Price to Earnings Multiple allakos.com|ALLK - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Allakos Therapeutics|ALLK - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Allakos|ALLK - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months allakos.com|ALLK - Net earnings per share growth this year|Earnings growth forecast for next year Allakos Inc.
General company analysis:ALLK Allakos Inc
Allakos Inc. specializes in innovative mast cell control for the therapy of severe allergic pathologies, making the aggregate consensus price target an indicator of market confidence in its scientific developments. This metric aggregates the target prices of leading analysts, allowing investors to assess the fundamental fair value of the asset and minimize the risks of sharp valuation revisions during the intervals between quarterly reports.
Competitors of Allakos Inc.
Analyst Consensus Forecast argenx.com (ARGX)|Price Target Chart BioNTech BNTX|Abivax SA - Price Target Chart|ADMA - Price Target Chart|PTGX: Price Target Chart|Immunovant, Inc. (IMVT) - Price Target Chart|kiniksa.com (KNSA) - Analyst Consensus Forecast|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|Kyverna Therapeutics (KYTX) - Price Target Chart|TLSA (tizianalifesciences.com) - Price Target Chart|Price Target Chart Cabaletta Bio|Price Target Chart VTYX|Analyst Consensus Forecast THTX|Analyst Consensus Forecast Avalo Therapeutics Inc (AVTX)|Price Target Chart Eledon Pharmaceuticals ELDN|Analyst Consensus Forecast agenusbio.com AGEN|CLYM - Price Target Chart|Average Forecast Price zurabio.com|aTyr (ATYR) - Price Target Chart|ADAG - Analyst Median Target|Consensus Target IMA|STTK: Fair Value Consensus|Analyst Consensus Forecast EQ|Analyst Median Target connectbiopharm.com|Price Target Chart Immunic IMUX|ATRA: Broker Consensus Forecast|InflaRx GmbH - Analyst Consensus Forecast|x4pharma.com (XFOR) - Consensus Target|ACET (adicetbio.com) - Consensus Target|CELU - Analyst Median Target|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Analyst Consensus Forecast Barinthus Biotherapeutics Corp|Price Target Chart Kezar Life Sciences (KZR)|Price Target Chart SABS (sabbiotherapeutics.com)|Price Target Chart Akari Therapeutics Plc AKTX|Enlivex Therapeutics Ltd - Price Target Chart|QTTB - Price Target Chart|GOVX - Analyst Consensus Forecast|Edesa Biotech, Inc. (EDSA) - Price Target Chart|Forecast Levels Chart IBIO (ibioinc.com)|CARM (Carisma Therapeutics Inc) - Analyst Consensus Forecast|XTLB: Fair Value Consensus|Analyst Consensus Forecast BOLT|Analyst Consensus Forecast hcwbiologics.com (HCWB)|Price Target Chart Aptevo Therapeutics Inc. APVO|Fair Value Consensus AIM|ADTX - Price Target Chart|GRI Bio Inc (GRI) - Consensus Target|XRTX: Analyst Consensus Forecast|Vyome Therapeutics (HIND) - Analyst Consensus Forecast|Consensus Target REVB|INDP: Fair Value Consensus|Analyst Consensus Forecast SCNI|Analyst Median Target calcimedica.com|Price Target Chart Affimed N.V. AFMD|HOOK - Consensus Target|IGMS - Price Target Chart|iteostherapeutics.com (ITOS) - Consensus Target|OCEA (Ocean Biomedical) - Consensus Target|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
